Table 1.
Analyses of histopathological parameters and survival between the groups
| BSBC | MFBC | MCBC | P | |
|---|---|---|---|---|
| (n = 89) | (n = 271) | (n = 147) | ||
| Age | 44.83 ± 9.67 (27–84) years | 47.27 ± 11.63 (19–84) years | 51.11 ± 11.94 (29–83) years | <0.001 |
| Menopause Status | <0.001 | |||
| Premenopausal | 56 (62.9%) | 168 (62.0%) | 60 (40.8%) | |
| Postmenopausal | 33 (37.1%) | 103 (38.0%) | 87 (59.2%) | |
| Number of tumors (İndex side for BSBC) | 3.12 ± 1.46 | 2.88 ± 1.54 | 2.3 ± 0.77 | <0.001 |
| Tumor size (mm) (İndex side for BSBC) | 55.88 ± 23.7 | 22.0 ± 12.0 | 34.9 ± 20.5 | <0.001 |
| Histological type | 0.001 | |||
| Invasive ductal | 75 (84.2%) | 198 (73%) | 134 (91.1%) | |
| Mix | 5 (5.6%) | 23 (8.4%) | 9 (6.1%) | |
| Invasive lobular | 6 (6.7%) | 33 (12.1%) | 4 (2.7%) | |
| Others | 3 (3.3%) | 14 (6.1%) | 0 | |
| Histological Grade (Modified Bloom Richardson) | <0.001 | |||
| I | 10 (11.5%) | 40 (15.0%) | 34 (23.1%) | |
| II | 66 (75.9%) | 113 (42.3%) | 36 (24.5%) | |
| III | 11 (12.6%) | 114 (42.7%) | 77 (52.4%) | |
| Lymphatic vascular invasion | <0.001 | |||
| Positive | 68 (76.4%) | 134 (49.4%) | 77 (42.5%) | |
| Negative | 21 (23.6%) | 137 (50.6%) | 70 (47.6%) | |
| Lymph node involvement | <0.001 | |||
| N0 | 0 | 128 (47.2%) | 68 (46.3%) | |
| N1 | 17 (19.1%) | 83 (30.6%) | 17 (11.6%) | |
| N2 | 41 (46.1%) | 40 (14.8%) | 34 (23.1%) | |
| N3 | 31 (34.8%) | 20 (7.4%) | 28 (19.0%) | |
| Estrogen receptor status | 0.515 | |||
| Positive | 53 (59.6%) | 147 (54.8%) | 87 (59.2%) | |
| Negative | 36 (40.4%) | 124 (45.8%) | 60 (40.8%) | |
| Progesterone receptor status | 0.193 | |||
| Positive | 69 (77.5%) | 195 (72.0%) | 98 (66.7%) | |
| Negative | 20 (22.5%) | 76 (28.0%) | 49 (33.3%) | |
| HER2/neu status | 0.02 | |||
| Positive | 8 (9.0%) | 16 (5.9%) | 24 (14.2%) | |
| Negative | 73 (90.1%) | 255 (94.1%) | 123 (83.7%) | |
| Molecular subtypes | 0.03 | |||
| Luminal A | 46 (51.7%) | 135 (49.82%) | 69 (46.9%) | |
| Luminal B | 16 (18.08%) | 51 (18.8%) | 19 (12.9%) | |
| Triple negative | 19 (21.3%) | 69 (25.5%) | 35 (23.8%) | |
| HER2 type | 8 (9.0%) | 16 (5.9%) | 24 (16.3%) | |
| Type of surgery | <0,001 | |||
| BCS + SLN | 0 | 132 (48.7%) | 32 (21.8%) | |
| BCS + AD | 23 (25.8%) | 105 (38.7%) | 4 (2.7%) | |
| MST + SLN | 13 (14.6%) | 11 (4.1%) | 30 (20.4%) | |
| MRM | 53 (59.6%) | 23 (8.5%) | 81 (55.1%) | |
| Adjuvant treatment modalities | Not applied | |||
| Chemotherapy | 87 (97.7%) | 141 (52.0%) | 80 (54.4%) | |
| Radiotherapy | 89 (100%) | 225 (83.0%) | 75 (51.0%) | |
| Endocrine therapy | 60 (67.4%) | 151 (55.7%) | 85 (57.8%) | |
| Targeted therapy | 8 (9.0%) | 12 (4.4%) | 21 (14.2%) | |
| Local recurrence | 5 (5.6%) | 14 (5.2%) | 3 (2.0%) | 0.263 |
| Mortality | 7 (7.9%) | 22 (8.1%) | 12 (8.2%) | 0.996 |
AD: Axillary dissection; BCS: Breast conserving surgery; MRM: Modified radical mastectomy; MST: Mastectomy; SLN: Sentinel lymph node biopsy.